Galena Biopharma (NASDAQ:GALE) shareholders have had a rough 2014 so far, with the stock dipping over 50% from its highs just north of $7 to a recent share price of just over $3. The stock has been plagued by rumors and allegations of share price manipulation and a variety of other issues. But let's leave the rumors aside and focus on the fundamentals and the pipeline, the actual business behind the share price.

So is it time to buy the stock?

In the video below, from Market Checkup, the Motley Fool's health care-focused investing show, health care analysts Michael Douglass and David Williamson answer.